Brent Jones has over 25 years of ophthalmic experience in leadership impacting surgical and pharmaceutical strategic planning, marketing, sales, managed markets, reimbursement, financial management, business development and start-up. In his current role at Sun Ophthalmics, a newly formed ophthalmic pharmaceutical company, Mr. Jones is the National Sales Director, Ophthalmics. At Sun Ophthalmics, Mr. Jones has led the creation of an ophthalmic sales force and successfully executed the commercial launch of BromSite™ (bromfenac ophthalmic solution) 0.075%. Prior to this, Mr. Jones has held various leadership positions in sales, marketing and medical science with Bausch & Lomb, ISTA Pharmaceuticals and Santen Pharmaceutical Co., Ltd. During this time, Mr. Jones was a part of the leadership teams that launched, Quixin® (levofloxacin ophthalmic solution) 0.5%, Xibrom™ (bromfenac ophthalmic solution) 0.09%, Bromday™ (bromfenac) ophthalmic solution) 0.09% and PROLENSA™ (bromfenac ophthalmic solution) 0.07%. Mr. Jones began his ophthalmic career with Grieshaber AG and later Alcon following the acquisition of Grieshaber AG. Mr. Jones currently represents Sun Ophthalmics on the Corporate Advisory Board of TFOS (Tear Film & Ocular Science Society).